Journal of Clinical and Aesthetic Dermatology

APR 2017

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/811500

Contents of this Issue

Navigation

Page 11 of 64

VOL. 10, NO. 4 • APRIL 2017 • JCADONLINE.COM JOURNAL WATCH Topical treatment of seborrheic dermatitis A novel cosmetic antifungal/anti- inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: a open-label trial utilizing clinical evaluation and erythema-directed digital photography. Dall'oglio F, Tedeschi A, Fusto CM, et al. G Ital Dermatol Venereol. 2017 Jan 24. [Epub ahead of print] Synopsis: To measure safety and efficacy of a cosmetic topical gel (combination ciclopiroxolamine, lactoferrin, glycero-phosphoinositol, and aloe vera) to treat facial seborrheic dermatitis, investigators conducted an open-label, prospective, clinical trial (n=25) of individuals with mild-to- moderate facial seborrheic dermatitis who applied the study gel for 45 days. Using digital photography technology to assess dermatitis severity at Days 15 and 45, they found significant reduction in desquamation, erythema, and pruritus, with greater than 80-percent improvement in 48 percent of participants. Authors conclude that the study gel was effective and erythema- directed digital photography could be useful in the practice of clinical dermatology. PMID: 28121079 Efficacy and safety of cream containing climbazole/piroctone olamine for facial seborrheic dermatitis: a single-center, open-label split-face clinical study. Youn HJ, Kim SY, Park M, et al. Ann Dermatol. 2016;28(6):733–739. Epub 2016 Nov 23. Synopsis: To investigate effectiveness of a climbazole/piroctone olamine cream in treating seborrheic dermatitis caused by Malassezia species, researchers conducted a single-center, open-label, split-face study (right side: climbazole/piroctone olamine cream, left side: emollient cream) for four weeks in 24 patients with mild-to- moderate seborrheic dermatitis. Median values of casual sebum level and erythema showed better outcomes on the treatment sides compared to controls, with minimal inhibitory concentrations of fungi on the treatment sides of 0.625, 5, 0.625, and 2.5mg/mL for Malassezia restricta, M. globosa, M. sympodialis, and M. slooffiae, respectively, indicating antifungal activity. Authors conclude that the treatment cream appears to be useful in mild-to-moderate seborrheic dermatitis by reducing concentrations of Malassezia species. PMID: 27904273; PMCID: PMC5125955 Topical treatment of facial seborrheic dermatitis: a systematic review. Gupta AK, Versteeg SG. Am J Clin Dermatol. 2017;18(2):193–213. Synopsis: Authors reviewed the literature on topical treatments for facial seborrheic dermatitis and analyzed the results by grading evidence level, by qualitatively comparing results among and within studies. They found 32 eligible papers studying 18 topical treatments for facial seborrheic dermatitis. Based on those results, they found that four treatments (Promiseb ® , desonide, mometasone furoate, and pimecrolimus) showed the lowest recurrence rates, highest clearance rates, and the lowest severity scores, with four additional treatments (ciclopirox olamine, ketoconazole, lithium, and tacrolimus) showing consistent effectiveness via randomized controlled trials. PMID: 27804089 Benzocaine, lidocaine, tetracaine as topical anesthesia for aesthetic procedures Benzocaine/lidocaine/tetracaine cream: report of corneal damage and review. Boonsiri M, Marks KC, Ditre CM. J Clin Aesthet Dermatol. 2016;9(3):48–50. A quick look at the noteworthy articles in dermatology research April 2017 By Laura Alexander, PhD JCAD journal of clinical and aesthetic dermatology April 2017 • Volume 10 • Number 4 12

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - APR 2017